Cachexia, a condition characterized by muscle wasting and fatigue, often lurks beneath the surface of chronic illnesses such as cancer and renal failure and can make it harder to fight infections and recover from treatments. While the physical toll is significant, the financial burden can be as well. Cachexia’s destruction of muscle strength and energy…
One of my treasured childhood photographs shows my kindergarten class, with about twenty small children sitting on the grass near a lake. I was the unruly kid with sun-bleached hair sitting on the right side of the front row. Next to me sat my best friend who shared my love for roaming the thousands of…
Endevica Bio is working hard to develop a treatment for a vexing condition that can have a significant impact on cancer patients but isn’t widely known: cachexia. It’s a debilitating wasting syndrome that affects up to 80% of people with advanced cancer, according to the National Cancer Institute. Cacexia, which causes dramatic muscle loss, fatigue…
Think back to your first day of college or perhaps a job you started with a “first year class” of new hires. There was probably camaraderie among the group of newcomers and in the right environment, you likely helped each other learn, grow, and navigate new challenges. As CEO of Endevica Bio, a high-growth biotech…
NORTHBROOK, Ill., April 23, 2024 /PRNewswire/ Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity (DIO) rat study. This latest research solidifies Endevica Bio’s status as a world leader in the scientific understanding of the central melanocortin system. The company’s proof-of-concept MC4R agonist compound A07D…
Authors: Sandra M. Axiak-Bechtel, Stacey B. Leach, Jessica R. Newton-Northup, Rowan J. Milner, Stacey A. Fox-Alvarez, Lana I. Fagman, Kaylee A. Young, Deborah J. Tate, Zachary M. Wright, John D. Chretin, Justin W. Allen, Sean K. Yoshimoto, Kimberly A. Selting, Brian K. Flesner, Carrie R. White, Tracy Mills, Michael Aherne, Philip J. Bergman, LeAnn Qi, Kenneth A. Gruber, Michael F. Callahan Abstract Background The melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics…
Authors: Xinxia Zhu, Eric J. Roeland, Mason A. Norgard, Kenneth Gruber, Russell Potterfield, and Daniel Marks Abstract e15196 Background: We previously reported that peripheral administration of TCMCB07, a synthetic antagonist of the type 4 melanocortin receptor (MC4R), ameliorates cancer- and chronic kidney disease-associated cachexia in rats. In this study, we used a rat model of cisplatin…
Authors: LeAnn Kuhlmann Qi, Xinxia Zhu, Kenneth Gruber, Eric J. Roeland, Russell Potterfield, and Daniel Marks Abstract Background: Cachexia is a complex wasting syndrome characterized by anorexia, an involuntary loss of adipose tissue and lean body mass, and a paradoxical increase in energy catabolism. TCMCB07 is an optimized peptide antagonist of the melanocortin type 3 and…
Authors: Kenneth A. Gruber*Ren-Lai JiFabio GallazziShaokai JiangSteven R. Van DorenYa-Xiong TaoJessica Newton Northup Abstract During the development of a melanocortin (MC) peptide drug to treat the condition of cachexia (a hypermetabolic state producing lean body mass wasting), we were confronted with the need for peptide transport across the blood–brain barrier (BBB): the MC-4 receptors (MC4Rs)…
Authors: Sandra M. Axiak-Bechtel, Stacey B. Leach, David G. Scholten, Jessica R. Newton-Northup, Brendan J. Johnson, H. E. Durham, Kenneth A. Gruber, Michael F. Callahan Abstract The melanocortin-4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously…